InVivo Therapeutics to Exhibit at 2014 Congress of Neurological Surgeons Annual Meeting

2014 CNS Annual Meeting

CAMBRIDGE, Mass.--()--InVivo Therapeutics Holdings Corp. (NVIV) today announced the Company will be exhibiting at the 2014 Congress of Neurological Surgeons (CNS) Annual Meeting, to be held in Boston, MA October 18-22. The exhibit, InVivo’s first at a major medical conference, will focus on strengthening and expanding the Company’s neurosurgical network and increasing awareness about its ongoing clinical pilot study of the Neuro-Spinal Scaffold to treat acute spinal cord injury. InVivo will also host a social event in conjunction with the Congress, which is estimated to draw more than 3,000 attendees this year.

Mark Perrin, InVivo’s CEO, said, “The CNS annual conference is one of the premier meetings in the world for neurosurgeons. We are delighted to be exhibiting this year, not only because the Congress anticipates this will be one of the largest CNS gatherings in history, but because we look forward to connecting with our medical colleagues in the neurosurgical community to discuss our cutting-edge technology, and — more importantly — how this technology might forever change the lives of spinal cord injury patients.”

For more information about the 2014 CNS Annual Meeting, please visit their website: https://www.cns.org/annual-meeting-2014

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children’s Hospital and now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Contacts

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com

Contacts

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com